DOCSLIB.ORG

Gn-Annual-Review.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gn-Annual-Review.Pdf Global Network for Neglected Tropical Diseases Our mission is simple: We are working to end global suffering and death from neglected tropical diseases through proven-effective, low-cost treatments. The Global Network is fulfi lling this mission by raising the profi le of neglected tropical diseases and leveraging international resources to deliver treatments to the world’s poorest people. What are NTDs? Neglected tropical diseases (NTDs) are disabling, disfi guring and deadly diseases 1 impacting more than one billion people worldwide. These bacterial and parasitic infections are widespread among people in poor, rural communities—the majority of whom live on less than $2 per day. NTDs impair physical and cognitive development, cause adverse pregnancy outcomes, and limit adult productivity in the workforce. As a result, they cause billions of dollars in lost wages, all but ensuring that those at risk of infection remain trapped in a cycle of poverty and disease. Soil-Transmitted Helminths (intestinal worms) Over 1 BILLION infected. Soil-transmitted helminths include ascariasis, hookworm, and trichuriasis. Transmission occurs with lack of access to clean water and sanitation. STHs in children cause anemia, vitamin A defi ciency, stunted growth, malnutrition, intestinal obstruction, and impaired physical and cognitive development. LEADING THE FIGHT AGAINST DISEASES OF POVERTY Schistosomiasis (snail fever) Approximately 200 MILLION infected. Infection is caused by a blood-borne fl uke found in freshwater, which causes blood in urine or stool. This can lead to anemia and impaired growth and A low-cost, safe and development in children. In adults, life-threatening conditions of effective solution exists to end the suffering. For bladder cancer, kidney malfunction or liver and spleen damage approximately 50 cents may develop. 280,000 people die from schistosomiasis each year, per person per year we making it the most deadly of the NTDs. can treat seven of the most common NTDs – Onchocerciasis (river blindness) making the elimination Approximately 37 MILLION infected. Infection is caused by a of NTDs the “best buy” parasitic worm transmitted by bites from black fl ies. Symptoms in public health. include intense itching, disfi guring skin conditions and eye lesions 2 that can result in blindness. Lymphatic Filariasis (elephantiasis) Approximately 120 MILLION infected. Infection is caused by a mosquito-borne parasitic worm that damages the lymphatic system, causing gross disfi guration and incapacitation from swollen limbs and thickened, rough skin. The larvae circulate in the skin, causing intense irritation. Trachoma (blinding trachoma) Approximately 84 MILLION infected. The world’s leading cause of preventable blindness is a bacterial infection spread through fl ies, poor hygiene and direct contact with infectious discharge. Over time, the upper eyelid develops scar tissue, eventually turning inward and causing the eyelashes to scratch the cornea, resulting in blindness. LEADING THE FIGHT AGAINST DISEASES OF POVERTY CONTENTS I. From the Chair and President II. Our Advantage: A Network in Action III. Major Strides in NTD Control: Working to End the Neglect IV. Generating Global Momentum V. Looking Forward VI. Sabin Vaccine Institute VII. Financials 3 LEADING THE FIGHT AGAINST DISEASES OF POVERTY I. FROM THE CHAIR AND PRESIDENT FROM THE CHAIR Dear Friends, The Sabin Vaccine Institute continues to evolve and adapt while envisioning a world free of preventable diseases. Our work commemorates the legacy of the great Dr. Albert B. Sabin, whose tireless efforts in the fi elds of vaccine development and global medical diplomacy improved the lives of many people. In this tradition, and in parallel with our other global health programs, I am proud of the signifi cant progress we’ve made since our energetic launch of the Global Network for Neglected Tropical Diseases in 2006. The success of the Global Network members’ incipient work in delivering a rapid-impact drug package for NTD control to communities throughout Latin America, sub-Saharan Africa, and Southeast Asia has already treated millions and has set the stage for a dramatic 4 improvement in the health of the world’s poorest people. In addition, the Global Network’s support of community-directed treatment distribution helps to ensure that programs are locally sustainable. The one constant in today’s world is change. As technology advances, diseases re-emerge or become resistant to existing treatments, and demographics shift. Amid this change, Sabin looks to remain at the forefront of the fi ght against preventable illness. As we continue to grow and adapt, we will not falter in our dedication to help the world’s poorest break out of the cycle of poverty and disease. I applaud the efforts of the Global Network and its members to create a synergistic approach to NTD control through new global partnerships. In doing so, they advance NTD control as increasingly innovative and cost-effective. I hope that, through this Annual Review, you receive a snapshot of all the wonderful work we are doing through the Global Network and its members. With your help and support, the Global Network can continue to extend its reach into the world’s most underserved communities. Sincerely, Morton P. Hyman Chairman of the Board, Sabin Vaccine Institute LEADING THE FIGHT AGAINST DISEASES OF POVERTY Dear Friends, FROM THE PRESIDENT In the three years since we launched the Global Network at the Clinton Global Initiative, followed by a landmark donation from Legatum, we have experienced signifi cant growth as we deepen our commitment to fi ghting neglected tropical diseases around the world. Through the tremendous efforts of our Global Network members tens of millions of the world’s poorest people are currently receiving a low-cost rapid-impact package of essential NTD drugs, enabling them to break out of a devastating cycle of poverty and disease. As their name suggests, NTDs have traditionally been neglected by the international community. Over the past year, however, we have seen incredible momentum establishing NTDs as a critical policy issue in global health. We’ve witnessed world leaders taking action: President Bush called on the U.S. to invest $350 5 million to fi ght NTDs; UK government offi cials announced they will be contributing £50 million over the next fi ve years toward the control and elimination of NTDs; UN Secretary General Ban Ki-moon dramatically raised the profi le of NTDs at the UN Elders Meeting held in Atlanta; and for the fi rst time ever, the leaders of the G-8 put NTDs on the global health agenda. These exciting developments truly represent a paradigm shift in the way the global community understands and fi ghts NTDs. As we become more effective in our NTD control efforts—through expanded partnerships, greater outreach, and heightened public awareness and political momentum—we will come closer to eliminating poverty and allowing children and families to survive and thrive. In doing so, NTD control represents a key mechanism by which we can achieve UN Millennium Development Goals and targets. The Global Network 2008 Annual Review summarizes our programmatic and operational objectives and assesses the progress made in the past year. As we build on the tremendous momentum generated, we are delighted to work with you in continuing to end the neglect. Sincerely, Peter J. Hotez, MD, PhD President, Sabin Vaccine Institute LEADING THE FIGHT AGAINST DISEASES OF POVERTY II. OUR ADVANTAGE: A NETWORK IN ACTION We take the word “network” seriously. The key to our success is two-fold: we leverage the strength and resources of our global partnerships and we combine them with an effective and inexpensive rapid-impact package that combats the seven most common NTDs. We have found that investments work best when targeted directly at people in need. Through high effi ciency with minimal overhead, investments go fi rst and foremost to treating people suffering from NTDs. Our approach allows us to: In 2009, we will build on our network approach through the launch of an alliance 1. Coordinate with 7 of regional fi nancial and grantmaking platforms in Africa, Asia and Latin America. experienced global This innovative partnership model will leverage resources from the private and organizations in the public sectors to ensure that investments made result in treatments delivered. fi eld Donors invest in the Global Network because their money goes directly to people 2. Partner with local who know how to effi ciently and effectively get the job done. We have member governments to create organizations across the globe with unparalleled expertise in NTD control efforts; sustainable solutions we utilize a unique community approach that empowers individuals to become 3. Leverage resources and directly involved in prevention and treatment efforts; and we collaborate with investments pharmaceutical donation programs that provide access to life-improving and 4. Empower communities life-saving treatments at no or low cost. 5. Raise awareness and increase overall health outcomes LEADING THE FIGHT AGAINST DISEASES OF POVERTY In 1974, one in ten people RAPID-IMPACT PACKAGE: ONE OF THE “BEST BUYS” IN PUBLIC HEALTH in West Africa suffered from river blindness The rapid-impact package contains four drugs – delivered in combination – that (onchocerciasis). Over the next three decades treat the seven most common NTDs. The rapid-impact package needs to be given only a groundbreaking global health partnership emerged once a year at approximately 50 cents per person. It is the reason why to face this threat. The fi ghting NTDs is referred to as one of the “best buys” in public health. Onchocerciasis Control Programme (OCP) and Merck Most of the drugs needed to treat NTDs are donated by the pharmaceutical & Co., Inc’s MECTIZAN Donation Program came industry. These donations are valued at hundreds of millions of dollars each year together to provide ochocerciasis control and allow for the treatment of millions of people living with NTDs.
Load more

Recommended publications
  • TESTIMONY Peter J. Hotez MD, Phd President, Sabin Vaccine Institute
    TESTIMONY Peter J. Hotez MD, PhD President, Sabin Vaccine Institute “The Growing Threat of Cholera and Other Diseases in the Middle East” Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations Committee on Foreign Affairs United States House of Representatives March 2, 2016 Mr. Chairman and Members of the Subcommittee, thank you for the opportunity to speak with you today. I am Peter Hotez, a biomedical scientist and pediatrician. I am the dean of the National School of Tropical Medicine at Baylor College of Medicine and also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics based at the Texas Medical Center in Houston. I am also past president of the American Society of Tropical Medicine and Hygiene, and currently serve as President of the Sabin Vaccine Institute, a non-profit which develops vaccines for neglected tropical diseases (NTDs) through a product development partnership (PDP) model. This year I am also serving as US Science Envoy for the State Department and White House Office of Science and Technology Policy focusing on the urgency to develop vaccines for diseases that are emerging in the Middle East and North Africa due to the breakdowns in health systems in the ISIS occupied conflict zones in Syria, Iraq, Libya, and also Yemen. In my submitted written testimony I highlighted some of the successes in US global health policy, many of which can be attributed to the hard work of this Subcommittee working hand in glove with two presidential administrations since 2000. I cite evidence from the Global Burden of Disease Study (GBD) that brings together hundreds of scientists - I am also a part of this - who are measuring the impact of large scale global health programs.
    [Show full text]
  • Sabin in the News Recent Scientific Articles Sabin Vaccine Institute
    Home About Us News & Resources Support Sabin Sabin in the News October 2011 The Sabin Report | Volume 13 Issue 2 New York Times article featuring Dr. Peter Hotez's new study on increased Sabin Vaccine Institute Establishes a Houston prevalence of NTDs in Europe. Office Drs. Ciro de Quadros and In September 2011, the Zulfiqar Bhutta highlight Sabin Vaccine Institute the dire need for a dengue established offices in vaccine in an opinion Houston, Texas in the piece for GlobalPost. heart of the city's Texas Medical Center (TMC). The In an interview on Voice of new facilities will house the America Dr. Peter Hotez Sabin Vaccine Institute & focused on NTDs in Sub- Texas Children's Hospital Saharan Africa. Center for Vaccine Development, which will be An article by Dr. Neeraj operated in partnership Mistry was featured in a with Baylor College of special supplemental Medicine Department of section of the USA today, Pediatrics. Sabin Dr. Hotez and team at Sabin's new Houston facility titled "Neglected Diseases President, Dr. Peter J. in Developing Nations". Hotez will direct the new center. In an op-ed for the Houston Chronicle, Dr. The new space includes offices and laboratories through which the Peter Hotez writes about Sabin Vaccine Institute Product Development Partnership (PDP) will the establishment of the advance and strengthen its collaborative work in the field of vaccine new School of Tropical biotechnology. The change is the result of a year-long plan to expand Medicine at Baylor College the scope and depth of the Sabin PDP's partnership and to enhance of Medicine.
    [Show full text]
  • Peter Hotez, M.D., Ph.D. Biography
    Peter Hotez, MD, PhD, FASTMH, FAAP Peter J. Hotez, M.D., Ph.D., is professor of pediatrics and Molecular Virology and Microbiology at Baylor College of Medicine where he is also chief of a new Section of Pediatric Tropical Medicine and founding Dean of the National School of Tropical Medicine. In addition Prof. Hotez is the Texas Children's Hospital Endowed Chair of Tropical Pediatrics, and president of the Sabin Vaccine Institute. He will lead the new Sabin vaccine development program at Texas Children's Hospital and Baylor College of Medicine. He moves to BCM and Texas Children's from The George Washington University, where he has served as a Distinguished Research Professor and the Walter G. Ross Professor and Chair of the Department of Microbiology, Immunology and Tropical Medicine. Dr. Hotez is an internationally-recognized clinician and investigator in neglected tropical diseases and vaccine development. Diseases he studies include hookworm, schistosomiasis, Chagas disease, leishmaniasis, and malaria, among others, impacting hundreds of millions of children and adults worldwide. He obtained his undergraduate degree in molecular biophysics from Yale University in 1980, followed by a Ph.D. degree in biochemical parasitology from Rockefeller University in 1986 and a medical degree from Cornell University in 1987. He completed pediatric residency training at Massachusetts General Hospital from 1987 to 1989 and postdoctoral fellowship training in infectious diseases and molecular parasitology at Yale from 1989 to 1991. Dr. Hotez joined the Yale faculty as an assistant professor of pediatrics in 1992. He became an associate professor in 1995 before moving to the George Washington University as professor and chair in 2000.
    [Show full text]
  • Sabin Vaccine Report
    Volume VIII, Number 1 Sabin Vaccine Spring 2005 EPORT The newsletter of the Albert B. Sabin Vaccine InstituteR — dedicated to disease prevention www.sabin.org FDA Clears Human Hookworm Vaccine for Phase I Safety Trials Sabin/GW Researchers Receive Word on Investigational New Drug Status for Vaccine Clinical trials to test the safety of a gin safety trials is a major milestone for in individuals who suffer from hook- first-of-its-kind human hookworm vac- the human hookworm vaccine project,” worm infection.” cine will begin in the Washington, DC Hotez said. “It has taken an amazing Human hookworm infection is caused area in the coming weeks after the U.S. amount of our team’s effort to get us to by parasitic worms that fasten onto the Food and Drug Administration conferred the current stage of vaccine develop- inner layers of the small intestine using investigational new drug status on the ment. Of course, our ultimate goal is to their teeth-like projections and cause vaccine this past January. No current take this research to developing coun- blood loss at the attachment site. vaccine is available to prevent hook- tries where the vaccine will be tested Hookworm disease refers to the iron worm disease, which is one of the most Continued on page 4 common chronic infections of humans with an estimated 740 million cases in The village of Americaninhas, areas of rural poverty in the tropics in a rural part of Minas Gerais and subtropics. state in Brazil, is the focus of a The Human Hookworm Vaccine Ini- field study of hookworm dis- tiative (HHVI) is sponsored by the ease burden, being conducted Albert B.
    [Show full text]
  • 2015 Form 990 Or 990‐EZ
    ** PUBLIC DISCLOSURE COPY ** Return of Organization Exempt From Income Tax OMB No. 1545-0047 Form 990 Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations) 2015 Department of the Treasury | Do not enter social security numbers on this form as it may be made public. Open to Public Internal Revenue Service | Information about Form 990 and its instructions is at www.irs.gov/form990. Inspection A For the 2015 calendar year, or tax year beginning and ending B Check if C Name of organization D Employer identification number applicable: Address change Albert B. Sabin Vaccine Institute, Inc. Name change Doing business as 06-1389829 Initial return Number and street (or P.O. box if mail is not delivered to street address) Room/suite E Telephone number Final return/ 2000 Pennsylvania Avenue, NW 7100 202-842-8610 termin- ated City or town, state or province, country, and ZIP or foreign postal code G Gross receipts $ 17,938,597. Amended return Washington, DC 20006 H(a) Is this a group return Applica- tion F Name and address of principal officer:Amy Finan for subordinates? ~~ Yes X No pending same as C above H(b) Are all subordinates included? Yes No I Tax-exempt status: X 501(c)(3) 501(c) ( )§ (insert no.) 4947(a)(1) or 527 If "No," attach a list. (see instructions) J Website: | www.sabin.org H(c) Group exemption number | K Form of organization: X Corporation Trust Association Other | L Year of formation: 1994 M State of legal domicile: MD Part I Summary 1 Briefly describe the organization's mission or most significant activities: An organization of scientists, researchers, and advocates for a world free of needless suffering.
    [Show full text]
  • Bridging the Innovation Gap for Neglected Tropical Diseases in Mexico
    Bol Med Hosp Infant Mex 2011;68(2):138-146 article Bridging the innovation gap for neglected tropical diseases in Mexico: capacity building for the development of a new generation of antipoverty vaccines Maria Elena Bottazzi,1 Eric Dumonteil,2 Jesus G. Valenzuela,3 Miguel Betancourt-Cravioto,4 Roberto Tapia-Conyer,5 and Peter J. Hotez1,6 ABSTRACT The neglected tropical diseases (NTDs) represent a group of chronic parasitic and related infections that promote poverty because of their impact on child development, pregnancy, and worker productivity. The estimated 20 million Mexicans who live below the poverty line suf- fer disproportionately from a high prevalence of neglected tropical diseases such as amebiasis, Chagas disease, dengue, leishmaniasis, soil-transmitted helminth infections, trachoma, and vivax malaria. However, because the NTDs occur predominantly among the poor, new industrial and financial models are required to establish innovative technologies to address these conditions in Mexico and elsewhere in Latin America. In response, the Slim Initiative for Antipoverty Vaccine Development was established to foster a public/private partnership between key academic, government, and industrial institutions in the U.S. and Mexico. Initial emphasis will be placed on developing new vaccines for Chagas disease and leishmaniasis, two of the highest burden NTDs in Mexico and Mesoamerica. Key words: public/private partnerships, vaccines, product development, technology transfer, vaccine manufacture. InTRODuCTIOn infectious diseases that
    [Show full text]
  • Social and Economic Impact Review on Neglected Tropical Diseases
    ECONOMIC POLICY / BRIEFING PAPER in conjunction with Social and Economic Impact Review on Neglected Tropical Diseases Jeremiah Norris Carol Adelman Yulya Spantchak Kacie Marano November 2012 Hudson Institute’s Center for Science in Public Policy in conjunction with The Global Network for Neglected Tropical Diseases an initiative of the Sabin Vaccine Institute Social and Economic Impact Review on Neglected Tropical Diseases November 2012 Contributors Jeremiah Norris Carol Adelman Senior Fellow and Director Senior Fellow and Director Center for Science in Public Policy Center for Global Prosperity Yulya Spantchak Kacie Marano Research Fellow and Deputy Director Project Manager and Research Associate Center for Science in Public Policy Center for Science in Public Policy Table of Contents I. Executive Summary……………………………………………………………………...i II. Introduction…………………………………………………………………………….1 III. Background……….…………………………………………………………………...2 IV. The Macroeconomic Impact of NTDs………………………………………………...4 V. Integration…………………………………………………………………………….16 VI. Key NTD Policy Issues……………………………………………………………...19 VII. The Role of the Corporate Sector in NTDs…………………………………………21 VIII. Conclusions and Recommendations……………………………………………….22 Appendix A………………………………………………………………………………25 I. Executive Summary The Hudson Institute’s Center for Science in Public Policy entered into a partnership with the Sabin Vaccine Institute’s Global Network for Neglected Tropical Diseases (GNNTD) to undertake a comprehensive research and policy analysis study on the economic impact of neglected
    [Show full text]
  • Vaccinology in Latin America © 2018 Sabin Vaccine Institute
    Vaccinology in Latin America © 2018 Sabin Vaccine Institute. All rights reserved. The material in this document may be freely used for educational or noncommercial purposes, provided that the material is accompanied by an acknowledgement. The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world. For more information, visit www.sabin.org and follow us on Twitter, @SabinVaccine. Recommended citation: Andrus et al. Vaccinology in Latin America: A Resource for Immunization Managers. Washington, D.C.: Sabin Vaccine Institute; 2018. Design: Renée Saunders Translation: Silvia Colla Contents Preface ........................................................................................................................................................................................................................1 MODULE 1: EXISTING VACCINES AND VACCINES IN DEVELOPMENT ..................................................................................
    [Show full text]
  • Sabin Vaccine Report
    Volume IV, Number 1 Sabin Vaccine June 2001 EPORT The newsletter of the Albert B. Sabin Institute —dedicatedR to disease prevention www.sabin.org Walker’s Cay Colloquium Catalyzes Work on Cancer Vaccines and Immunotherapy 3rd Annual Sabin Institute-Sponsored Meeting Convened in March at Walker’s Cay, Abaco, Bahamas Thirty of the world’s leading cancer of the colloquium, said the meeting “was notherapy to learn from each other and vaccine scientists spent three days in a great success since it provided an ex- to discuss issues that are critical for the intense, unusually open discussions of cellent opportunity for top scientists in improvement of cancer treatments.” Jef- their newest research data and ideas at the field of tumor vaccines and immu- frey Schlom, head of the Laboratory of the Sabin Vaccine Institute’s Tumor Immunology and Biology Third Annual Walker’s Cay Col- at the National Cancer Institute loquium on Cancer Vaccines in also served as co-chair. The March. Their goal was to accel- Walker’s Cay Colloquium follows erate progress toward develop- a peer review format; emphasiz- ment of vaccines to treat and pre- ing an unusually open discussion vent various forms of cancer. of ideas and data so new they have Most of the renowned scientists not yet been published. It is reported learning new informa- multidisciplinary, involving ex- tion that will speed their own re- perts in oncology, immunology, search. Several said they formed microbiology, biochemistry, he- new, multi-institution collabora- matology and several other fields. tions at the meeting. It differs from most scientific Ralph A.
    [Show full text]
  • 22Nd Annual Albert B. Sabin Medal Award Ceremony Roger I. Glass
    nd Annual 22 Albert B. Sabin Gold Award Ceremony MedalPresented to Roger I. Glass, M.D., Ph.D. for his many contributions toward improving children’s health worldwide, including novel scientific research for the prevention of gastroenteritis from rotaviruses and noroviruses Tuesday, April 14, 2015 Bethesda North Marriott Hotel & Conference Center North Bethesda, MD Ceremony Program 5:30 PM REGISTRATION & REFRESHMENTS 6:30 PM WELCOME Peter J. Hotez, M.D., Ph.D. President, Sabin Vaccine Institute; Director, Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development; Dean, National School of Tropical Medicine at Baylor College of Medicine INTRODUCTION & PRESENTATION OF THE ALBERT B. SABIN GOLD MEDAL Walter A. Orenstein, M.D. Professor of Medicine and Pediatrics, Emory University; Associate Director, Emory Vaccine Center Mathuram Santosham, M.D., M.P.H. Professor of Pediatrics and International Health Director, Center for American Indian Health Johns Hopkins University ACCEPTANCE Roger I. Glass, M.D., Ph.D. Director, Fogarty International Center Associate Director for International Research National Institutes of Health 7:30 PM RECEPTION About Sabin Vaccine Institute The Sabin Vaccine Institute (Sabin) is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs). Since its founding in 1993 in honor of Dr. Albert B. Sabin, the developer of the oral polio vaccine, Sabin has been at the forefront of global efforts to eliminate, prevent, and cure infectious and neglected tropical diseases. Sabin develops new vaccines, advocates for increased use of existing vaccines and promotes expanded access to affordable medical treatments in collaboration with governments, academic institutions, scientists, medical professionals and other non-profit organizations.
    [Show full text]
  • SABIN VACCINE REPORT the Newsletter of the Albert B
    SABIN VACCINE REPORT the newsletter of the Albert B. Sabin Vaccine Institute at Georgetown University Volume I, Number 1, September 1998 IN THIS ISSUE Institute Announces Sabin Vaccine Institute Announces Sabin-Hilleman Fellows Program Sabin and Hilleman are the inspiration for program aimed at promoting Sabin-Hilleman Fellows Program vaccinology and immunology. BY ERICA SEIGUER By participating in existing internships, or in projects 1 In keeping with one of its central missions, the Albert designed through a collaboration between the stu- B. Sabin Vaccine Institute has recently created the Sabin- dent and mentor, the Sabin-Hilleman Fellows will Neal Nathanson: New OAR Head Brings Diplomacy, Toughness Hilleman Fellows Program. A tribute to the pioneering work be exposed to the latest in vaccine design and imple- Renowned for his work on polio of two great figures in vaccinology, Albert B. Sabin and Maurice mentation. Possible projects might include intern- epidemiology, Nathanson filled the vacancy left by Bill Paul in November 1997. R. Hilleman, the Fellows Program will nurture talented high ships at the Global Programme for Vaccines and Im- 1 school students and undergraduates as they pursue their in- munization at the World Health Organization or in Op/Ed terests in the health sciences, particularly in vaccinology and a research laboratory at the National Institutes of Vaccines as an Instrument of immunology. Sabin Vaccine Institute Chairman H.R. Shep- Health. International Diplomacy 2 herd, a close friend of both Hilleman and the late Sabin, un- The Institute will begin the selection pro- derscores that the program is designed to encourage the next cess in February 1999, when application materials A Model of Government-Industry Collaboration, Avirons Intranasal generation of scientists and health professionals to dedicate are due.
    [Show full text]
  • SABIN VACCINE REPORT the Newsletter of the Albert B
    SABIN VACCINE REPORT the newsletter of the Albert B. Sabin Vaccine Institute at Georgetown University Volume II, Number 1, March 1999 IN THIS ISSUE Gates donates $100 million for childrens vaccines Rotavirus vaccine developed The newly developed vaccine for BY JOHN CLYMER AND DIANE MYERS Decreasing the lag time intestinal disease could improve the health of over 500 million children Microsoft billionaires Bill and Melinda Gates have Why is the Gates Foundation program of such importance? made a $100 million gift to establish a program to acceler- New, life-saving vaccines generally are in broad use in in- worldwide. ate access to new vaccines for children in developing na- dustrialized countries several years before they become widely 1 tions. The goal of the Bill and Melinda Gates Children’s used in developing countries where the need is greatest. This Vaccine Program’s is to significantly reduce the time it cur- time lag in vaccine “uptake” is due to economic, logistical rently takes for vaccines to reach children living in poor coun- and other challenges. tries. “We have a social imperative to work together to The initiative is a program of the William H. Gates SPECIAL REPORT: MALARIA address this basic inequity,” said Bill Gates, trustee of the A report on the impact of malaria on Foundation and will Fiset photo by PATH/J. William H. Gates Foundation. global health, the search for a vaccine, be administered by Sabin Vaccine Institute chairman and the risks travelers face when the Program for H. R. “Shep” Shepherd ap- visiting malaria-endemic areas. Appropriate plauded Gates’ vision and the es- 2-5 Technology in tablishment of the Children’s Vac- Health (PATH).
    [Show full text]